Clinical Medicine Reviews in Therapeutics

Tocilizumab for the Treatment of Adults with Moderate to Severe Rheumatoid Arthritis

Submit a Paper

Clinical Medicine Reviews in Therapeutics 2011:3


Published on 29 May 2011

DOI: 10.4137/CMRT.S1622

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics


Rheumatoid arthritis (RA) is a chronic, autoimmune disorder primarily affecting the joints but is also associated with many systemic features. Inflammatory cytokines such as IL-6 are abundantly detected in the synovial fluid. IL-6 plays a role in autoimmunity by promoting antibody production and T cell proliferation. The chronicity of inflammation observed in RA can also be partly explained by the effect of IL-6 on leukocyte migration and angiogenesis. Additionally, joint destruction may be mediated by IL-6 dependent osteoclastogenesis. Collectively, these findings prompted the development of an anti IL-6 receptor antibody (tocilizumab). Currently, tocilizumab is indicated for treating patients with moderate to severe RA as monotherapy or in combination with methotrexate, in whom disease modifying anti-rheumatic drugs or anti-TNFs have failed. The side effect profile is manageable but includes infections, decrease in neutrophil, increases in cholesterol and liver transaminases. Tocilizumab has expanded the treatment options of RA.



BibTex citation   (BIBDESK, LATEX)

Warning: include_once(templates/common_sidebar/image_rotator.php): failed to open stream: No such file or directory in /var/www/insights/views/generic/right_column_signup_specific.php on line 11

Warning: include_once(): Failed opening 'templates/common_sidebar/image_rotator.php' for inclusion (include_path='.:/usr/share/pear:/usr/share/php') in /var/www/insights/views/generic/right_column_signup_specific.php on line 11